Takeda Pharmaceutical Co Ltd (TAK)
13.07
-0.16
(-1.21%)
USD |
NYSE |
Apr 25, 16:00
13.06
-0.01
(-0.08%)
Pre-Market: 20:00
Takeda Pharmaceutical Revenue (Quarterly): 7.526B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.526B |
| September 30, 2023 | 7.221B |
| June 30, 2023 | 7.715B |
| March 31, 2023 | 7.239B |
| December 31, 2022 | 7.778B |
| September 30, 2022 | 7.256B |
| June 30, 2022 | 7.505B |
| March 31, 2022 | 7.517B |
| December 31, 2021 | 7.929B |
| September 30, 2021 | 7.675B |
| June 30, 2021 | 8.675B |
| March 31, 2021 | 7.273B |
| December 31, 2020 | 8.012B |
| September 30, 2020 | 7.434B |
| June 30, 2020 | 7.451B |
| March 31, 2020 | 7.086B |
| December 31, 2019 | 7.903B |
| September 30, 2019 | 7.562B |
| June 30, 2019 | 7.726B |
| March 31, 2019 | 6.513B |
| December 31, 2018 | 4.430B |
| September 30, 2018 | 3.865B |
| June 30, 2018 | 4.124B |
| March 31, 2018 | 3.699B |
| December 31, 2017 | 4.322B |
| Date | Value |
|---|---|
| September 30, 2017 | 3.905B |
| June 30, 2017 | 4.034B |
| March 31, 2017 | 3.660B |
| December 31, 2016 | 4.261B |
| September 30, 2016 | 4.072B |
| June 30, 2016 | 4.018B |
| March 31, 2016 | 3.594B |
| December 31, 2015 | 4.027B |
| September 30, 2015 | 3.747B |
| June 30, 2015 | 3.679B |
| March 31, 2015 | 3.675B |
| December 31, 2014 | 4.273B |
| September 30, 2014 | 4.235B |
| June 30, 2014 | 4.025B |
| March 31, 2014 | 3.935B |
| December 31, 2013 | 4.569B |
| September 30, 2013 | 4.225B |
| June 30, 2013 | 4.155B |
| March 31, 2013 | 3.995B |
| December 31, 2012 | 4.953B |
| September 30, 2012 | 4.942B |
| June 30, 2012 | 4.969B |
| March 31, 2012 | 4.813B |
| December 31, 2011 | 5.493B |
| September 30, 2011 | 4.442B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.086B
Minimum
Mar 2020
8.675B
Maximum
Jun 2021
7.604B
Average
7.526B
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Hoya Corp | 1.359B |
| Otsuka Holdings Co Ltd | 3.654B |
| Nxera Pharma Co Ltd | 49.39M |
| PeptiDream Inc | 41.78M |
| Stemcell Holdings Inc | 3.403M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 716.00M |
| Total Expenses (Quarterly) | 7.076B |
| EPS Diluted (Quarterly) | 0.2265 |
| Enterprise Value | 71.84B |
| Gross Profit Margin (Quarterly) | 65.85% |
| Profit Margin (Quarterly) | 9.51% |
| Earnings Yield | 3.07% |
| Operating Earnings Yield | 6.02% |
| Normalized Earnings Yield | 3.071 |